Molecular pathology for classification of tumors and for efficacy prediction of qualified therapies can be a swiftly growing subject.Just lately released systematic reviews are corresponding with toxicity details of randomized trials with bevacizumab furthermore chemotherapy. In an open-label, randomized, section III trial, the efficacy and securit